WHO WE ARE

Management Team & Advisory Board

External Review Board

  • Marc Appel, JD, MBA

    CEO
    Orange Grove Bio

  • Colleen Cuffaro, PhD

    Principal, Canaan Partners

  • Daniel Forler, PhD

    Senior Director, Early Licensing, Bayer U.S. Pharma (LEAPs program)

  • John D. Haley, PhD

    Associate Professor, Pathology, Stony Brook University; Director, Developmental Therapeutics, Stony Brook Cancer Center; Director, Stony Brook University Proteomics Center

  • Kenton C. Hasson, PhD

    Director of Strategic Partnerships, ANGLE plc

  • Brandy Houser, PhD

    Site Head, New York, NY, Celdara Medical

  • Thomas D. Ippolito

    Vice President, Clinical and Regulatory Affairs, Chembio Diagnostic Systems, Inc.

  • Sathapana (Sam) Kongsamut, PhD

    President, Rudder Serendip LLC.

  • Jonathan Mandelbaum, PhD

    Senior Associate,  Private Equity | Venture Capital, OrbiMed

  • Michael E. Marino, PhD

    Manager, Drug Product Analytical Technologies, Regeneron Pharmaceuticals

  • Annie Mitsak, PhD

    Senior Associate, Omega Funds

  • Stephanie C. Oestreich, PhD, MPA

    EVP, Head BRIDGEs Partnerships North America, Evotec

  • Christopher O’Donnell, PhD

    Executive Director, External Science & Innovation and Principal, Pfizer Ventures.

  • Barbara Sawitsky

    Director of Patents and Licensing, New York Blood Center

  • Tara Sharif, PhD

    Managing Director WestPark Capital, Inc.

  • Stephanie Stehman, PhD

    Principal, Osage University Partners

  • James R. Tonra, PhD

    SVP Preclinical Development, BeyondSpring

  • Heather Walsh, PhD

    Director of External Innovation, Baxter

  • Leigh Zawel, PhD

    Executive Partner, MPM Capital; CSO, Cullinan Oncology

  • Leah Lipsich, PhD

    Executive Director, Program Direction, Immunology & Inflammation, Regeneron Pharmaceuticals, Inc.

  • Peter Young, MBA

    Venture Partner
    Pappas Capital